107 related articles for article (PubMed ID: 7354887)
1. Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects.
Camanni F; Genazzani AR; Massara F; La Rosa R; Cocchi D; Müller EE
Neuroendocrinology; 1980; 30(1):2-6. PubMed ID: 7354887
[TBL] [Abstract][Full Text] [Related]
2. Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia.
Ghigo E; Ciccarelli E; Novelli A; Massobrio M; Müller EE; Camanni F
J Endocrinol Invest; 1985 Feb; 8(1):35-40. PubMed ID: 3989236
[TBL] [Abstract][Full Text] [Related]
3. Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia.
DeLeo V; Cella SG; Camanni F; Genazzani AR; Müller EE
Horm Metab Res; 1983 Sep; 15(9):439-43. PubMed ID: 6642414
[TBL] [Abstract][Full Text] [Related]
4. Impaired prolactin responsiveness to dopamine antagonists in acromegaly.
Camanni F; Massara F; Santià M; Molinatti GM; Müller EE
Metabolism; 1982 Nov; 31(11):1090-5. PubMed ID: 7132736
[TBL] [Abstract][Full Text] [Related]
5. Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone.
Massara F; Genazzani AR; Camanni F; De Leo V; Molinatti GM; Müller EE
Fertil Steril; 1981 Feb; 35(2):149-54. PubMed ID: 7202740
[TBL] [Abstract][Full Text] [Related]
6. Multicentric experience on the acute effect of nomifensine in hyperprolactinemic women.
Minuto F; Barbarino A; Baviera G; Mazzocchi G; De Marinis L; Leonardi R; Bernasconi D; Menini E; Maira G; Anile C
J Endocrinol Invest; 1984 Apr; 7(2):137-40. PubMed ID: 6725869
[TBL] [Abstract][Full Text] [Related]
7. Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects.
Massara F; Camanni F; Amoroso A; Molinatti GM; Müller EE
Acta Endocrinol (Copenh); 1981 May; 97(1):48-53. PubMed ID: 7223316
[TBL] [Abstract][Full Text] [Related]
8. Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia.
Sekiya K; Karashima T; Ikuyama S; Muta K; Kato K; Ibayashi H
Endocrinol Jpn; 1985 Apr; 32(2):207-14. PubMed ID: 4042986
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors.
Kamoi K; Tchuchida I; Sato H; Tanaka R; Ishiguro T; Kaneko K; Iwasaki Y; Shibata A
J Clin Endocrinol Metab; 1981 Dec; 53(6):1285-7. PubMed ID: 7298805
[TBL] [Abstract][Full Text] [Related]
10. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Rodriguez-Arnao MD; Peters JR; Foord SM; Dieguez C; Edwards C; Gomez-Pan A; Hall R; Newcombe RG; Scanlon MF
J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271
[TBL] [Abstract][Full Text] [Related]
11. Different rebound rise in plasma prolactin during the postdopamine infusion phase in puerperal women and patients with pathological hyperprolactinemia.
Genazzani AR; Cavagnini F; Picotti GB; Ghigo E; De Leo V; Galva MD; Maraschini C; Muller EE
J Clin Endocrinol Metab; 1983 Dec; 57(6):1159-63. PubMed ID: 6630411
[TBL] [Abstract][Full Text] [Related]
12. Nomifensine: diagnostic test in hyperprolactinemic states.
Müller EE; Genazzani AR; Murru S
J Clin Endocrinol Metab; 1978 Dec; 47(6):1352-7. PubMed ID: 263356
[TBL] [Abstract][Full Text] [Related]
13. Plasma prolactin levels in the inferior petrosal sinuses in various pituitary disorders during perihypophyseal phlebography.
Lombardi G; Merola B; Miletto P; Colao A; De Chiara G; Iaccarino V; Spaziante R; Di Renzo G; Taglialatela M; Annunziato L
Neuroendocrinology; 1987 Oct; 46(4):333-8. PubMed ID: 3670552
[TBL] [Abstract][Full Text] [Related]
14. Integrity of central dopaminergic system in women with postpartum hyperprolactinemia.
Rao R; Scommegna A; Frohman LA
Am J Obstet Gynecol; 1982 Aug; 143(8):883-7. PubMed ID: 7102764
[TBL] [Abstract][Full Text] [Related]
15. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
Melis GB; Gambacciani M; Paoletti AM; Beneventi F; Mais V; Baroldi P; Fioretti P
J Clin Endocrinol Metab; 1987 Sep; 65(3):541-5. PubMed ID: 3624413
[TBL] [Abstract][Full Text] [Related]
16. PRL as a novel potent cofactor for platelet aggregation.
Wallaschofski H; Donné M; Eigenthaler M; Hentschel B; Faber R; Stepan H; Koksch M; Lohmann T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5912-9. PubMed ID: 11739463
[TBL] [Abstract][Full Text] [Related]
17. Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test.
Fideleff HL; Azaretzky M; Boquete HR; Pujol AB; Honfi M; Suárez MG; Fideleff G; Giaccio AV
J Pediatr Endocrinol Metab; 2003 Feb; 16(2):163-7. PubMed ID: 12713252
[TBL] [Abstract][Full Text] [Related]
18. Subnormal prolactin responsiveness to thyrotropin-releasing hormone (TRH) in women with primary empty sella syndrome.
Celani MF; Giambuzzi G; Simoni M; Montanini V
J Endocrinol Invest; 1987 Aug; 10(4):421-5. PubMed ID: 3119699
[TBL] [Abstract][Full Text] [Related]
19. Suppression of serum immunoreactive human epidermal growth factor by acute increase in prolactin in women.
Chen CF; Kurachi H; Miyake A; Aono T; Tanizawa O
Endocrinol Jpn; 1989 Apr; 36(2):203-9. PubMed ID: 2506003
[TBL] [Abstract][Full Text] [Related]
20. Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma.
Hanew K; Sato S; Sasaki A; Goh M; Shimizu Y; Murakami O; Yoshinaga K
Endocrinol Jpn; 1985 Dec; 32(6):811-7. PubMed ID: 3938732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
